The British journal of psychiatry : the journal of mental science · 2010
Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsoi Daniel Tai-yin, Porwal Mamta, Webster Angela Claire
Аннотация
BACKGROUND: The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain.
AIMS: To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.
METHOD: Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia.
RESULTS: Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 months (RR = 2.78, P = 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy (P = 0.002) but not at 6 months (P = 0.37). There was no significant difference in positive (P = 0.28) or negative symptoms (P = 0.49) between the bupropion and the placebo group.
CONCLUSIONS: Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.
AIMS: To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.
METHOD: Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia.
RESULTS: Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 months (RR = 2.78, P = 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy (P = 0.002) but not at 6 months (P = 0.37). There was no significant difference in positive (P = 0.28) or negative symptoms (P = 0.49) between the bupropion and the placebo group.
CONCLUSIONS: Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.